Integrity Bio competitors

Robert was appointed President and Chief Executive Officer of Cytokinetics in January 2007 and has been a member of our Board of Directors since then. Previously, he served as Cytokinetics’ President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Robert has served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. He served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools, designed to further science education and exploration in the spirit of repairing the world. Robert served on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He also served on the Boards of San Francisco’s Contemporary Jewish Museum and the Anti-Defamation League. Robert was named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. He is a member of the Aspen Global Leadership Network and has moderated seminars related to science, health, and technology at Aspen Action Forums. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Robert was a fan of mountain bluegrass music long before it was fashionable and has been known to carry a harmonica in his briefcase, much to the dismay of nearby hotel guests. He enjoys trying to keep up with his wife Dana and daughters, Brittany and Bridget, as well as his Bernese mountain dog, Baron, on long hikes in the Presidio.

Phillip Frost is a Board Member at Ym Biosciences Inc., General Partner at Peregrine Ventures Management Ltd, and Board Member at Protalix Ltd and is based in Miami Beach, Florida. He has worked as Governor at American Stock Exchange; Board Member at COCRYSTAL PHARMA, INC.; and Chairman:Dermatology at Mount Sinai. Phillip works or has worked as TRUSTEE at Frost Nevada Investments Trust, BOARD MEMBER at Shanghai Institute for Advanced Immunochemical Studies, and BOARD MEMBER at Smithsonian Institution. He studied at University of Pennsylvania until 1957, Yeshiva University, and Albert Einstein College of Medicine until 1961.

Roy Smythe, M.D., is the Chief Executive Officer of SomaLogic, Inc., a leading-edge biotechnology company headquartered in Boulder, Colorado. During the course of his career, he has been an internationally recognized surgeon, biomedical scientist, academician, health system administrator and healthcare business entrepreneur. While in medical school at Texas A&M, he was a Charles A. Dana Foundation Scholar at the University of Pennsylvania School of Medicine and the Wharton School of Business. Following medical school, Smythe trained in general surgery, surgical oncology and thoracic surgery and completed a postdoctoral research fellowship in molecular therapeutics at the University of Pennsylvania. His medical and translational research career then began at the University of Texas MD Anderson Cancer Center, where he was the recipient of NIH and numerous other funding awards. He subsequently chaired the Department of Surgery at Baylor Scott & White Health System and the Texas A&M Health Science Center College of Medicine, where he was the Roney Endowed Chair, and later became the Medical Director of Innovation and Executive Vice President for Institute Development before moving into expanded roles in corporate healthcare. Smythe came to SomaLogic from Royal Philips, where he served as Global Chief Medical Officer for Strategy and Partnerships. Before joining Philips, he served as Chief Medical Officer at Valence Health, a Chicago-based healthcare company. He held the same title previously at AVIA, a healthcare technology accelerator. A highly sought-after lecturer and the author of more than 300 papers, abstracts and essays in academic, literary and humanities publications, Smythe is also currently a member of more than 20 U.S. national learned societies.